Dr. Andrew Snyder (Monash University) joins the show to discuss the current biotech landscape: rising M&A and IPO activity, ...

But what if one of them encounters significant competition soon? That's what some investors believe might happen, given ...

CARVYKTI® (ciltacabtagene autoleucel; cilta-cel) net trade sales increased 62% versus first quarter of 2025 to approximately ...

Significant news coverage and COVID-19 flashbacks have driven investors into biotech stocks over the past week.

Krystal Biotech, Inc. reported Q1 2026 net income of US$55.93 million, with basic EPS from continuing operations rising to US$1.91, and later in May the company’s leadership participated in the BofA ...

An expert from Northway Biotech and Lithuania’s Minister of Economy and Innovation talk about how the country is poised to be ...

FDA drug approvals are reshaping biotech stocks—track key decisions, FDA leadership turmoil, and volatility. Click for a look ...

Bayer has removed a protein therapeutic for hypertension and a treatment for diabetic neuropathic pain from its phase 1 ...

Biotech stocks are gaining momentum on M&A activity, cancer drug launches and upcoming autoimmune treatment data.

Animal-free dairy is entering a reset phase, with one startup abandoning the “build first, scale later” approach in favor of ...

Some proposed clinical trial rules could create hurdles for smaller countries while failing to ensure high quality and ...